| Dr Sepalika Wasanthalal, MD | |
|
5053 South Congress Ave, Suite 201, Atlantis, FL 33462 | |
| (561) 357-9060 | |
| (561) 357-9460 |
| Full Name | Dr Sepalika Wasanthalal |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 44 Years |
| Location | 5053 South Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386741114 | NPI | - | NPPES |
| 2451100200 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | ME0067628 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Universal Kidney Center Of Boynton Beach | Boynton beach, FL | Dialysis facility |
| Universal Kidney Center Of Margate-coral Springs Llc | Margate, FL | Dialysis facility |
| Jfk Medical Center | Atlantis, FL | Hospital |
| Bethesda Hospital Inc | Boynton beach, FL | Hospital |
| Entity Name | West Palm Beach Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235231465 PECOS PAC ID: 7618878216 Enrollment ID: O20040116000450 |
News Archive
A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.
Only one out of more than 1,900 people evaluated met the American Heart Association definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.
A study of gene activity in the brain's hippocampus, led by UT Southwestern researchers, has identified marked differences between the region's anterior and posterior portions. The findings, published today in Neuron, could shed light on a variety of brain disorders that involve the hippocampus and may eventually help lead to new, targeted treatments.
› Verified 7 days ago
| Entity Name | Inpatient Consultants Of Florida, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396795597 PECOS PAC ID: 4789614785 Enrollment ID: O20050819000018 |
News Archive
A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.
Only one out of more than 1,900 people evaluated met the American Heart Association definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.
A study of gene activity in the brain's hippocampus, led by UT Southwestern researchers, has identified marked differences between the region's anterior and posterior portions. The findings, published today in Neuron, could shed light on a variety of brain disorders that involve the hippocampus and may eventually help lead to new, targeted treatments.
› Verified 7 days ago
| Entity Name | Accountable Care Hospitalist Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659640282 PECOS PAC ID: 3678733342 Enrollment ID: O20120404000760 |
News Archive
A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.
Only one out of more than 1,900 people evaluated met the American Heart Association definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.
A study of gene activity in the brain's hippocampus, led by UT Southwestern researchers, has identified marked differences between the region's anterior and posterior portions. The findings, published today in Neuron, could shed light on a variety of brain disorders that involve the hippocampus and may eventually help lead to new, targeted treatments.
› Verified 7 days ago
| Entity Name | Hospitalist Group Of The Palm Beaches Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801249990 PECOS PAC ID: 1254615057 Enrollment ID: O20170222001866 |
News Archive
A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.
Only one out of more than 1,900 people evaluated met the American Heart Association definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.
A study of gene activity in the brain's hippocampus, led by UT Southwestern researchers, has identified marked differences between the region's anterior and posterior portions. The findings, published today in Neuron, could shed light on a variety of brain disorders that involve the hippocampus and may eventually help lead to new, targeted treatments.
› Verified 7 days ago
| Entity Name | Quality Medical Consultant Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003216391 PECOS PAC ID: 7517243447 Enrollment ID: O20170407001493 |
News Archive
A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.
Only one out of more than 1,900 people evaluated met the American Heart Association definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.
A study of gene activity in the brain's hippocampus, led by UT Southwestern researchers, has identified marked differences between the region's anterior and posterior portions. The findings, published today in Neuron, could shed light on a variety of brain disorders that involve the hippocampus and may eventually help lead to new, targeted treatments.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sepalika Wasanthalal, MD 460 Pine Hollow Ln, West Palm Beach, FL 33413-2255 Ph: (561) 684-6129 | Dr Sepalika Wasanthalal, MD 5053 South Congress Ave, Suite 201, Atlantis, FL 33462 Ph: (561) 357-9060 |
News Archive
A new study of breast cancer survivors may help physicians ease a common side effect of cancer treatments. The collaborative research by Eva Sevick, Ph.D., Director of the Center for Molecular Imaging at the University of Texas Health Science Center in Houston, and Caroline Fife, M.D., Director of the Memorial Herman Wound Care Clinic at UTHSC, could bring relief to millions.
Only one out of more than 1,900 people evaluated met the American Heart Association definition of ideal cardiovascular health, according to a new study led by researchers at the University of Pittsburgh School of Medicine. Their findings were recently published online in Circulation.
Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.
Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.
A study of gene activity in the brain's hippocampus, led by UT Southwestern researchers, has identified marked differences between the region's anterior and posterior portions. The findings, published today in Neuron, could shed light on a variety of brain disorders that involve the hippocampus and may eventually help lead to new, targeted treatments.
› Verified 7 days ago
James Heron, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #218, Atlantis, FL 33462 Phone: 561-968-0307 Fax: 561-968-7673 | |
Roberto Von Sohsten, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Dr. Samantha Sylvonne Kerry-ann Nicholson-spence, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1273 | |
Alexander Chernobelsky, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, #102, Atlantis, FL 33462 Phone: 561-967-5033 Fax: 561-967-8974 | |
Denzil S Seedial, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5401 S Congress Ave, Ste 204, Atlantis, FL 33462 Phone: 561-967-4118 Fax: 561-967-3463 | |
Dr. Daphnee Marie Hutchinson, D.O. Nephrology Medicare: Medicare Enrolled Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-1750 | |
Dr. Farahnaz Angella, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 180 Jfk Dr, Suite 311, Atlantis, FL 33462 Phone: 561-434-0353 Fax: 561-357-0869 |